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Carcinoma of the larynx accounts for 25-30 percent of
all carcinomas of the head and neck. Early carcinomas
of the larynx (Tis or T1) and severe dysplasia are pre-
sently treated with either radiation therapy or surgery
alone. Radiation therapy, however, has significant disad-
vantages including mucositis during and for potential
prolonged periods after therapy, permanently altered
voice quality, dysphagia, chondroradionecrosis of the
larynx and trachea, and the extensive length of therapy
(6-7 weeks). Surgical therapy for early carcinomas of the
larynx includes performing a partial cordectomy or
hemilaryngectomy. Although cure rates are high, surgical
removal of portions of the vocal cord or hemilarynx
results in significant alteration of the quality of voice.
Photodynamic therapy has been demonstrated to be
effective in the treatment of early carcinomas of the
larynx, Tis and T1, with cure rates of 90% with follow-
up to 236 months. The advantage of PDT therapy for
early carcinomas of the larynx is the ability to preserve
normal endolaryngeal tissue while effectively treating
the carcinomas. This results in improved laryngeal func-
tion and voice quality. Furthermore, PDT requires a
short duration of therapy as compared to radiation
therapy, is repeatable and carries less risk than surgical
therapy and is performed as an outpatient noninvasive
treatment. Importantly, the use of PDT does not
preclude the use of radiotherapy or surgery in the future
for new primary or recurrent disease.
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